GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) » Definitions » COGS-to-Revenue

Harbin Gloria Pharmaceuticals Co (SZSE:002437) COGS-to-Revenue : 0.46 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Harbin Gloria Pharmaceuticals Co COGS-to-Revenue?

Harbin Gloria Pharmaceuticals Co's Cost of Goods Sold for the three months ended in Mar. 2024 was ¥274 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥593 Mil.

Harbin Gloria Pharmaceuticals Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.46.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Harbin Gloria Pharmaceuticals Co's Gross Margin % for the three months ended in Mar. 2024 was 53.81%.

Harbin Gloria Pharmaceuticals Co COGS-to-Revenue Historical Data

The historical data trend for Harbin Gloria Pharmaceuticals Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Gloria Pharmaceuticals Co COGS-to-Revenue Chart

Harbin Gloria Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.26 0.26 0.43 0.42

Harbin Gloria Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.02 0.22 1.14 0.46

Harbin Gloria Pharmaceuticals Co COGS-to-Revenue Calculation

Harbin Gloria Pharmaceuticals Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1092.711 / 2626.039
=0.42

Harbin Gloria Pharmaceuticals Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=273.973 / 593.133
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harbin Gloria Pharmaceuticals Co  (SZSE:002437) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Harbin Gloria Pharmaceuticals Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 273.973 / 593.133
=53.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Harbin Gloria Pharmaceuticals Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Harbin Gloria Pharmaceuticals Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) » Definitions » COGS-to-Revenue
Comparable Companies
SHSE:688073 SZSE:300194 SZSE:300401 SZSE:002728 SZSE:000566 SHSE:600488 SHSE:605199 SHSE:600789 SZSE:002793 SHSE:688553 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
Beijing Road No 29, Harbin Economic and Technological Development Zone, Harbin, CHN, 150025
Website
http://www.gloria.cc
Harbin Gloria Pharmaceuticals Co Ltd is a tech biopharmaceutical enterprise. It is engaged in the research, development, production, and sale of pharmaceutical products primarily in China. The company offers cardiovascular drugs; cardiac cerebrovascular medication; vitamins and minerals; urinary tract drugs; urinary system medication; anti-tumor medication; endocrine system drugs; anti-infective drugs; digestive system medication; respiratory medication; and other medications.
Executives
Guo Yun Pei Independent director
Wang Yu Supervisors
Yang Hong Bing Director
Diao Xiu Qiang Directors, executives
Liu Yue Yin Securities Affairs Representative
Guo Lei Feng Directors, Directors, and Executives
Li Jun Ling Director
Yang Hai Feng Executives
Zhang Su Mei Supervisors
Zhu Ji Man Director

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Headlines

No Headlines